Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Mecasermin (Increlex) vs Somapacitan (Sogroya)
An educational, source-based comparison of Mecasermin (Increlex) and Somapacitan (Sogroya) — how each peptide works, what it's researched for, and what to know before going deeper.
Recombinant human insulin-like growth factor-1 (rhIGF-1) that binds IGF-1 receptors to promote linear growth in children with severe primary IGF-1 deficiency or GH gene deletion with anti-GH antibodies.
- Severe primary IGF-1 deficiency
- Growth failure with GH gene deletion and neutralizing GH antibodies
- • FDA-approved.
- • Hypoglycemia — must be taken with food.
- • Tonsillar hypertrophy, intracranial hypertension reported.
Once-weekly growth hormone analog for adults and children with GHD.
GH analog with a non-covalent albumin-binding side chain that extends half-life, enabling once-weekly subcutaneous administration with sustained IGF-1 elevation.
- Adult growth hormone deficiency
- Pediatric GH deficiency
- • FDA-approved.
- • Monitor glucose; injection-site reactions possible.
Mecasermin (Increlex) vs Somapacitan (Sogroya) — Key differences
- Class: Mecasermin (Increlex) is classified as IGF-1 · Endocrine, while Somapacitan (Sogroya) is GH Analog · Endocrine.
- Primary research focus: Mecasermin (Increlex) — severe primary igf-1 deficiency; Somapacitan (Sogroya) — adult growth hormone deficiency.
- Tag: FDA-Approved · Endocrine vs FDA-Approved · Endocrine.